

ALAMEDA COUNTY

OCT 0 2 2019

CLERK OF THE SUPER; OR COURT

NANCY E. O'MALLEY

District Attorney of Alameda County

Matthew L. Beltramo, Assistant District Attorney

(State Bar No. 184796)

7677 Oakport Street, Suite 650

Oakland, CA 94621

Telephone: (510) 383-8600

Facsimile: (510) 383-8615

Attorneys for Plaintiff

(For list of additional Plaintiff's counsel,

see Appendix)

SUPERIOR COURT OF THE STATE OF CALIFORNIA

IN AND FOR THE COUNTY OF ALAMEDA

PEOPLE OF THE STATE OF CALIFORNIA.

Plaintiff,

VS.

MY PILLOW, INC., a Minnesota Corporation; DOES 1-10.

Defendants.

Case No.: RH9 037519

COMPLAINT FOR EQUITABLE RELIEF, INCLUDING AN INJUNCTION, RESTITUTION AND CIVIL PENALTIES (Bus. & Prof. Code, §§ 17200, et seq., 17207 and 17500, et seq.)

[VERIFIED ANSWER REQUIRED PURSUANT TO CODE OF CIVIL PROCEDURE SECTION 446]

Plaintiff, the People of the State of California, appearing through its attorneys: Nancy E. O'Malley, District Attorney of Alameda County, by Matthew L. Beltramo, Assistant District Attorney; Lori E. Frugoli, District Attorney of Marin County, by Andres H. Perez, Deputy District Attorney; Jeannine Pacioni, District Attorney of Monterey County, by Amy Anderson, Deputy District Attorney; Allison Haley, District Attorney of Napa County, by Patrick Collins, Deputy District Attorney; Todd Spitzer, District Attorney of Orange County, by Tracy E. Hughes, Senior Deputy District Attorney;

Page 1

Complaint

7 8

3

4

5

6

10 11

9

12

13 14

15

16 17

18 19

20

21 22

23

24

25 26

12

11

13 14

15

16

injunction.

17

18

19 .20

> 21 22

23

24 25

26 27

28

Stephanie A. Bridgett, District Attorney of Shasta County, by Anand "Lucky" Jesrani, Senior Deputy District Attorney; Krishna Abrams, District Attorney of Solano County, by Diane M. Newman, Deputy District Attorney; and Jill R. Ravitch, District Attorney of Sonoma County, by Matthew T. Cheever, Deputy District Attorney, alleges the following: **INTRODUCTION**

This complaint seeks for the second time in three years to hold Defendant MyPillow, Inc., accountable for disseminating false and misleading advertisements related to its principal product, bed pillows. As with the prior action, which resulted in a stipulated judgment and injunction, the advertisements in question here involved health-related claims related to specific disease conditions, such as sleep apnea. And with the prior action, the advertising claims at issue here lack adequate scientific substantiation. To make matters worse, Defendant inaccurately portrayed the sole "study" upon which the new claims were purportedly based, asserting that it was "double-blind" and "placebocontrolled" when, in fact, it was not. These advertising claims directly violated the terms of the prior

THE PARTIES

- 2. The Plaintiff is the People of the State of California (hereinafter "the People" or "Plaintiff"). The People are represented by and through the District Attorneys referenced above. Each of these District Attorneys has authority to bring this case on behalf of the People, pursuant to the Unfair Competition Law (Bus. & Prof. Code §§, 17200, et seq.) and the False Advertising Law (Bus. & Prof. Code, §§ 17500, et seq.), and specifically Business and Professions Code sections 17203, 17204, 17206, 17207, 17535 and 17536.
- This suit is brought by the People in the public interest and in order to protect the millions of consumers in the State of California who were and are exposed to Defendants'

advertisements. The People have a substantial state interest in eliminating and preventing the deceptive practices alleged herein, ensuring an honest and fair marketplace, and vindicating the terms of the prior judgment discussed below.

- 4. Defendant My Pillow, Inc., is a Minnesota corporation. It will hereinafter be referred to as "Defendant My Pillow" or simply "My Pillow."
- 5. Defendant My Pillow has a principal place of business located at 343 East 82nd Street, Suite 100, Chaska, MN 55318.
- 6. Plaintiff is ignorant of the true names and capacities of defendants sued herein as DOES 1 through 10, inclusive, and therefore sues those defendants by these fictitious names. Plaintiff alleges that said defendants, and each of them, performed each of the acts alleged below and otherwise aided, abetted, and assisted in each of these acts, with the requisite legal state of mind.
- 7. Defendant My Pillow and Defendants DOES 1-10 shall be referred to collectively as "Defendants."
- 8. Whenever reference is made in this complaint to any act of Defendants, such reference shall be deemed to mean that each defendant's officers, employees, agents, or representatives did, ratified or authorized such act while actively engaged in the management, direction or control of the affairs of said corporate defendant or while acting within the scope and course of their duties.

JURISDICTION AND VENUE

- 9. This Court has subject matter jurisdiction over this action pursuant to Business and Professions Code section 17203, 17204, 17206, 17207, 17535 and 17536.
- 10. This Court has jurisdiction over Defendants pursuant to Code of Civil Procedure section 410.10 because the causes of action alleged herein arise out of business activities that occurred, and advertisements and advertising claims that were disseminated, throughout the State of California, including the counties of Alameda, Napa, Solano, Sonoma, Marin, Monterey, Orange, Santa Clara, Santa Cruz, and Shasta. Further, Defendant made substantial sales of their products to citizens of

California, including those residing in the counties referenced above, during the period of time at issue.

11. Venue is proper in this Court because the violations of law herein alleged occurred within Alameda County (and elsewhere throughout the State of California).

GENERAL ALLEGATIONS

- 12. Defendants are in the business of developing, manufacturing, packaging, promoting, advertising and selling bedding products, including pillows, marketed under the brand name "MyPillow."
- 13. Defendants promoted, advertised and sold these products throughout the counties of Alameda, Marin, Monterey, Napa, Orange, Santa Clara, Santa Cruz, Shasta, Solano and Sonoma, and elsewhere in the State of California.
- 14. Defendants advertise these products through a number of media channels, including but not limited to television, radio, internet, and displays erected inside retail outlets.
- 15. Many of these advertisements tout the alleged health benefits of using Defendants' products, including its pillow products, as more fully described below.

THE 2016 STIPULATED JUDGMENT

- 16. As noted above, this is the second time in three years that the People have brought a consumer protection action in this Court against My Pillow as result of its advertising practices.
- 17. The first stemmed from an advertising campaign in which My Pillow claimed that its pillow products could "help with" or otherwise improve the symptoms of a variety of disease conditions, including but not limited to fibromyalgia, insomnia, migraines, TMJ (temporomandibular joint disorder), restless leg syndrome, sleep apnea, and snoring.
- 18. This campaign included direct advertising claims, such as "MyPillow Can Help Sleep Apnea" and "MyPillow can help your TMJ," and accompanying consumer testimonials that made reference to the product's purported effect on these disease conditions.
 - 19. The People filed the first action against My Pillow on or about October 26, 2016. (See

3

5

6 7

8 9

10

11 12

13

14

15 16

17

18

19 20

21 22

23

24

25 26

27

28

20. The complaint alleged that Defendant My Pillow had violated the False Advertising Law (Bus. & Prof. Code, §§ 17500 et seq.) and the Unfair Competition Law (Bus. & Prof. Code, §§ 17200, et seq.) by, among other things:

- a. Making health and wellness claims about MyPillow products that were not supported by competent and reliable scientific evidence. These included claims regarding the effects, efficacy or attributes of MyPillow products on a variety of disease conditions, including fibromyalgia, insomnia, migraines, sleep apnea, snoring, TMJ (temporomandibular joint disorder), and restless leg syndrome and; and
- b. Failing to disclose a material financial connection between MyPillow and an "official" endorser of Defendant's products.
- Filed simultaneously with the complaint was a Stipulation for Entry of Final Judgment, 21. attached to which was a proposed copy of the Final Judgment Pursuant to Stipulation (hereinafter "2016 Stipulated Judgment"). The Stipulation was signed both by attorneys for the People and My Pillow, and also by My Pillow's Chief Executive Officer, Michael Lindell.
- The 2016 Stipulated Judgment was approved and entered by the court on or about October 31, 2016. A file-endorsed copy is attached hereto at Exhibit A, and incorporated by reference herein.1
- 23. Among other things, the 2016 Stipulated Judgment enjoined My Pillow from: "Making or disseminating...any claim or advertisement...that any pillow product...can affect the structure or function of the human body or cure, mitigate, treat or prevent any DISEASE or symptom thereof unless: [¶] (i) the pillow product in question complies with California Health and Safety Code section

Due to a clerical error, the judgment was entered twice. This error was corrected by the Court (the Honorable Morris Jacobson) by way of an "Order Correcting Docket Regarding Entry of Judgment," dated November 30, 2016.

111550, pertaining to the sale of medical devices; and [¶] at the time of making any such claim or representation, it is true, not misleading, and Defendant already has in its possession and relies on at least one ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY conducted on the product or a SUBSTANTIALLY EQUIVALENT DEVICE."

- 24. The term "DISEASE" was defined to mean: "any damage to an organ, part, structure, or system of the body such that it does not function properly or a state of health leading to such dysfunction, including any mental health disease or disorder, and specifically includes the following non-exclusive list of such diseases: allergies, asthma, anxiety, fibromyalgia, insomnia, restless leg syndrome, spine pain (including cervical pain), *sleep apnea*, *snoring* or temporal mandibular joint syndrome (TMJ)." (Emphasis added.)
- 25. The term "ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY" was defined to mean: "a clinical study conducted on humans that is randomized, *double-blind*, *placebo-controlled*, conducted by persons qualified by training and experience to conduct such study, with statistically significant results as to the claim, advertisement or representation at issue." (Emphasis added.)
- 26. The 2016 Stipulated Judgment also enjoined My Pillow from violating a number of California statutes, including:
 - a. "California Health and Safety Code section 110400, by delivering in commerce any device that is falsely advertised";
 - b. "California Health and Safety Code section 111440, by manufacturing, selling, delivering, holding, or offering for sale any device that is misbranded";
 - c. "California Health and Safety Code section 111445, by misbranding any device";
 - d. "California Health and Safety Code section 111450, by delivering in commerce any device that is misbranded;" and
 - e. "California Civil Code section 1770(a)(5), by representing that Defendants' goods or

services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities which they do not have or that Defendants have a sponsorship, approval, statutes, affiliation, or connection which they not have."

27. Finally, the 2016 Stipulated Judgment enjoined My Pillow from relying on any endorsement based on an endorser with whom Defendant had a "material connection" unless Defendant also "disclose[s], clearly and prominently and in visual proximity to any written claim or in temporal proximity to any claim conveyed by voice, any material connection between such user or endorser and any Defendant." The term "material connection" was defined to mean "any relationship that materially affects the weight or credibility of the ... endorsement and that would not reasonably be expected by consumers, including, but not limited to monetary payments from the endorser to the seller, or from the seller to the endorser, or the provision of goods, services, or other benefits to anyone providing a user testimonial or endorsement."

THE 2018 "SLEEP STUDY"


- 28. Beginning in approximately November 2018 and continuing through March 2019 at the earliest, Defendants conducted an advertising campaign that was not only false and misleading, but directly violated the terms of the 2016 Stipulated Judgment.
- 29. This new campaign centered around a purportedly scientific study conducted on the MyPillow "classic" pillow. The study was entitled, "Physicians Identify A Commercially-Available Pillow That Objectively Improves Sleep Parameters. A double-blind randomized controlled trial of a consumer-marketed pillow, using pre and post Sleep EEG monitoring." Hereinafter, this study shall be referred to as the "Sleep Study".
 - 30. Upon information and belief, the Sleep Study was performed by "Sleep4Life LLC."
- 31. According to its website, Sleep4Life LLC is a company that conducts sleep testing services for other companies, including skilled nursing facilities.
 - 32. The CEO of Sleep4Life LLC is one Simcha Cohen. According to the Sleep Study, Mr.

Cohen "initiated the research by contacting pillow companies in a request to investigate their products to assist elderly institutionalized individuals improve their sleep."

- 33. The Sleep Study listed a number of co-authors. All of these individuals purport to be medical doctors, with the exception of Mr. Cohen.
- 34. According to the Sleep Study's authors, its goal was "to study the physiological changes in sleep ... for people sleeping on traditional down pillows versus the foam MyPillow® Classic Pillow."
- 35. Upon information and belief, the Sleep Study was never published in a medical journal, nor was it ever peer-reviewed.
 - 36. Nevertheless, Defendants predicated a new advertising campaign on the Sleep Study.
- 37. This campaign was disseminated through all media channels, including television, radio and the internet.
- 38. For example, in or about December 2018, Defendant My Pillow's website (www.mypillow.com) featured a webpage touting the purported results of the Sleep Study: www.mypillow.com/study. That dedicated webpage contained a scrolling banner reading: "NEW SLEEP STUDY PROVED: 100% of sleep study participants INCREASED their amount of DEEP SLEEP with MyPillow! 96% of participants experienced LESS SLEEP INTERRUPTIONS! HELPS REDUCE daytime fatigue! HELPS REDUCE snoring! HELPS IMPROVE the QUALITY of your sleep! A large percentage of participants refused to stop using their MyPillow and switch to a down pillow!"
- 39. The internet advertisements further stated that the results of the Sleep Study were "based on a double-blind randomized placebo-controlled study comparing study participants' sleep between their original pillow, MyPillow® Classic pillow, and goose down pillows."

40. The Sleep Study also featured prominently in video advertisements that were run in late 2018 and early 2019. These included advertisements attesting that MyPillow "reduce[d] snoring" and that "96% of positional sleep apnea sufferers reported a reduction in their symptoms." The following is an example:





Results are based on a double-blind randomized placebo-controlled study comparing study participants' sleep between their original pillow, MyPillow Classic pillow, and goose down pillows.

- 42. The purportedly clinical basis for these advertising claims was emphasized in audio tracks that overlaid these video ads. In one advertisement, for example, the CEO of My Pillow, Michael Lindell, states: "Sleep is one of the most important things for your health. And I've always said that MyPillow is one of the most important things to your sleep. And now a recent clinical sleep study proved it. ..." (Emphasis added.)
- 43. Upon information and belief, advertisements that referenced or relied upon the Sleep Study were broadcast in radio spots purchased by My Pillow.

- 44. Advertisements regarding the Sleep Study were false and misleading in a number of material ways. For example, the study was not "placebo-controlled." Due to the purported refusal of some participants to switch to a "placebo" pillow, the authors of the study explicitly stated that they "were not including any comparative results between MyPillow and the placebo."
- 45. The Sleep Study also was not "double-blind." A double-blind study is one in which neither the participants nor the administrators know who is receiving a particular treatment. The classic example of a double-blind study is one involving pharmaceuticals, in which neither the participant nor the administrator knows which pill is the drug being tested and which is the placebo.
- 46. In the Sleep Study, by contrast, the "treatments" in question were two completely distinguishable products: the MyPillow pillow, which is a stuffed with foam, and a goose down pillow, which was (presumably) stuffed with feathers. Unlike a true double-blind scenario, both the administrators of and the participants in the Sleep Study would readily know which "treatment" they were using, as foam-stuffed pillows and down-stuffed pillows feel and weigh differently. This common-sense fact is borne out by the Sleep Study itself, which claimed that "many participants refused to switch to down placebo pillows" if true, an obvious sign that the participants could tell the difference between the two products.
- 47. In or about January 2019, after being confronted with the fact that the Sleep Study was not actually "double-blind" or "placebo-controlled," Defendants changed the description of the Study to read as follows: "Results are based on a blind clinical study comparing study participants' sleep between their original pillow and My Pillow Classic pillow." However, even this revised description was false and misleading; the Sleep Study was not "blind" to participants, who would obviously know the difference between their original pillows and the foam-stuffed MyPillow product.
- 48. Because the Sleep Study was not "double-blind" or "placebo-controlled" it did not qualify as a "ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY" under the

-16

terms of the 2016 Stipulated Judgment. (See Exhibit A, at p. 3, lines 13-17.)

- 49. Because the Sleep Study did not qualify as an "ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY," the 2016 Stipulated Judgment barred Defendants from using that study as a basis for any claim the MyPillow product could "cure, mitigate, treat or prevent," any disease condition, including specifically "sleep apnea" and "snoring."
- 50. Thus, the advertising claims that referenced either sleep apnea and/or snoring were in direct violation of the terms of the 2016 Stipulated Judgment.
- 51. Upon information and belief, Defendants described the Sleep Study as "place-controlled" and "double-blind" (when it was neither) in an attempt to appear compliant with the terms of the 2016 Stipulated Judgment.

B. Failure to Disclose Material Connections

- 52. The Sleep Study was solely funded by Defendant My Pillow.
- 53. Upon information and belief, this funding was paid to Sleep4Life LLC, the company that conducted the Sleep Study.
- 54. However, nowhere was this payment clearly and conspicuously disclosed by Defendants in their advertisements referencing the Sleep Study.
- Advertising (16 C.F.R. § 255, et seq.), the weight consumers place on the reported results of a scientific study "could be materially affected by knowing the advertiser had funded the project." (16 C.F.R § 255.5.) Thus, an advertiser "should clearly and conspicuously disclose" the payment it has made to any research group.
- 56. Defendants' failure to clearly and conspicuously disclose its funding of the Sleep Study rendered the advertisements false and misleading under California law.

C. Other False and Materially Misleading Aspects of the Sleep Study

57. In addition to the issues describe above, the Sleep Study and the advertising campaign it

- a. As set forth above, Defendants' advertisements claimed that "100% of sleep study participants INCREASED their amount of DEEP SLEEP with MyPillow!" This claim was false and misleading, because the study did not so find. Indeed, midway through the Sleep Study advertising campaign, Defendants changed this claim to say merely that there was a "Significant increase in amount of sleep...."
- b. Defendants' advertisements also claimed that "96% of participants experienced LESS SLEEP INTERRUPTIONS!" This figure ("96%") appears to have come from that portion of the Sleep Study addressed to "apnea hypopnea index," not "sleep interruptions." Moreover, to the extent these and other advertising claims that reference "96%" were actually referring to sleep apnea, the portion of the study addressed to this condition went on to say that "33% of the participants showed an adverse effect: increased hypopnic episodes." (Emphasis added.) This contrary finding was not disclosed in any of the advertisements in question.
- 58. The Sleep Study was also executed in a highly flawed manner. For example, the participants were all taken from one age-group (adults over 50 years old), one location (Brooklyn, New York) and one ethnic group (Russians), all without any articulated scientific rationale. In addition, there was a "high dropout rate" 55% of the participants dropped out. Another eight percent were excluded for other reasons. None of these deficits were disclosed in Defendants' advertising.
- 59. As a result of these (and other) flaws, the Sleep Study was neither a competent nor reliable basis for any of the advertising claims made about it, rendering all such advertisements false and misleading.

² "Hypopnea" is a blockage of the airway.

- 60. As set forth above, Defendant marketed its MyPillow products on the basis of claims that those products could improve one or more disease conditions, including sleep apnea.
- 61. These claims rendered the products "medical devices" as that term is defined in Health and Safety Code section 109920.
- 62. These medical devices were not approved for sale pursuant to Health and Safety Code section 111550.
- 63. Further, Defendants delivered and offered for delivery these medical devices on the basis of the false advertisements set forth above, in violation of Health and Safety Code section 110400.
- 64. Defendants' use of the false and misleading advertisements referenced above rendered its products "misbranded" in violation of Health and Safety Code section 111445 and 111550.
- 65. Further, by virtue of the advertisements set forth above, Defendants represented that products had sponsorship, approval, characteristics, ingredients, use, benefits or quantities which they do not have, in violation of Civil Code section 1770(a)(5).

FIRST CAUSE OF ACTION VIOLATIONS OF BUSINESS & PROFESSIONS CODE SECTION 17500 (Untrue or Misleading Advertising)

- 66. The People re-allege and incorporate by reference Paragraphs 1 through 65 of this Complaint as though fully set forth herein.
- 67. Beginning at an exact date which is unknown to Plaintiff, but within three years prior to the filing of this complaint, Defendants, with the intent directly or indirectly to dispose of property or to perform services, or to induce members of the public to enter into obligations relating thereto, made or disseminated or caused to be made or disseminated before the public in this state statements concerning such property, services or obligations which were untrue or misleading and which Defendants knew or

reasonably should have known were untrue or misleading, as prohibited by Business & Professions Code section 17500. Such statements included but are not limited to all of the claims set forth in Paragraphs 28 through 65, above.

68. As a result of these violations, Defendants are subject to civil penalties, pursuant to Business & Professions Code section 17536, and to injunctive relief and the payment of restitution, pursuant to Business & Professions Code section 17535.

SECOND CAUSE OF ACTION VIOLATIONS OF BUSINESS AND PROFESSIONS CODE SECTION 17200 (Unfair Competition)

- 69. Plaintiff realleges and incorporates by reference Paragraphs 1 through 68 of this Complaint as though fully set forth herein.
- 70. Beginning at an exact date which is unknown to the People, but within four years prior to the filing of this complaint, Defendants engaged in a course of conduct that constituted acts of unfair competition, as defined by Business & Professions Code section 17200, by committing the following acts and violations of law:
 - a. Disseminating unfair, deceptive, untrue or misleading advertising;
 - b. Violating the following California laws:
 - Business & Professions Code section 17500, as set forth in the First Cause of Action;
 - ii. Health & Safety Code section 110400, by delivering into commerce a medical device that was falsely advertised;
 - iii. Health & Safety Code section 111440, by selling or offering to sell a medical device that is misbranded;
 - iv. Health & Safety Code section 111445, by misbranding a medical device;
 - v. Health & Safety Code section 111450, by delivering into commerce a medical device that is misbranded;

vi. Civil Code section 1770(a)(5), by representing that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits or quantities which they do not have.

71. As a result of this conduct, Defendants are subject to civil penalties, pursuant to Business & Professions Code section 17206, and to injunctive relief and the payment of restitution, pursuant to Business & Professions Code sections 17203 and 17204.

THIRD CAUSE OF ACTION VIOLATION OF BUSINESS AND PROFESSIONS CODE SECTION 17207 (Violation of Injunction)

- 72. Plaintiff realleges and incorporates by reference Paragraphs 1 through 71 of this Complaint as though fully set forth herein.
- 73. Beginning at an exact date which is unknown to the People, but within four years prior to the filing of this complaint, Defendants violated Business & Professions Code section 17207(a), by violating the injunctive terms of the 2016 Stipulated Judgment. These violations include:
 - a. "making or disseminating ... directly or indirectly ... a claim or advertisement that any pillow product, including but not limited to any pillow marketed or sold under the trade name 'MyPillow,' can affect the structure or function of the human body or cure, mitigate, treat, or prevent any DISEASE or symptom thereof," without "complying with California Health and Safety Code section 111550, pertaining to the sale of medical devices" and without having in its possession an 'ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY' conducted on the product or a 'SUBSTANTIALLY EQUIVALENT DEVICE.'" (Ex. A, 2016 Stipulated Judgment, Par. 5.A., at pp. 2-3)³;
 - b. Violating the provisions of Health and Safety Code sections 110400, 111440, 111445

³ The capitalized terms have the meanings set forth in the 2016 Stipulated Judgment and quoted above.

- c. Violating the provisions of Civil Code section 1770(a)(5). (See Ex. A, 2016 Stipulated Judgment, Par. 5.C., at p. 3.)
- 74. Upon information and belief, the violations described above were intentional. Among other things, My Pillow's current chief executive officer signed the stipulation for entry of judgment and therefore had actual knowledge of the terms of the 2016 Stipulated Judgment. In addition, the judgment explicitly required that it be distributed to "current principals, officers, directors and managers ... and to all personnel, agents and representatives having primary authority over sales, advertising or policy responsibility with respect to the subject matter" of the Judgment. Further, the use of the terms "placebo-controlled" and "double-blind" made it appear as if the Sleep Study, and the advertisements it gave rise to, complied with the 2016 Stipulated Judgment, when they did not.
- 75. The violations described above were of a continuing nature, as set forth in Business & Professions Code section 17207(a).
- 76. Defendants are subject to civil penalties, pursuant to Business & Professions Code section 17207(a) for each day in which the conduct occurred.

PRAYER FOR RELIEF

WHEREFORE, the People pray for relief as follows:

- 77. For a preliminary and permanent injunction, pursuant to Business & Professions Code sections 17203, 17204, and 17535, restraining and enjoining Defendants, from making, disseminating, or causing to be made or disseminated any false or misleading statements as set forth in the First Cause of Action, above, or from engaging in or performing, directly or indirectly, any acts of unfair competition as set forth in the Second Cause of Action, above.
- 78. That Defendants be ordered to pay a civil penalty of up to \$2,500.00 for each act of false advertising and/or unfair competition, pursuant to Business and Professions Code sections 17206 and 17536.

Page 17

.

- 79. That Defendant be ordered to pay a civil penalty of up to \$6,000.00 for each act in violation of Business and Professions Code sections 17207(a) and for each day in which a continuing violation occurred.
 - 80. That Defendants be ordered to pay restitution as required under law.
 - 81. That the People recover its costs of suit herein.
- 82. That the People be given such other and further relief as the nature of this case may require and this Court deems proper to fully and successfully dissipate the effects of the unlawful and unfair acts complained of in this complaint.

Date: October 1, 2019

Nancy E. O'Malley Alameda County District Attorney

By:

Matthew L. Beltramo
Assistant District Attorney and on
behalf of the District Attorney's Offices
listed on the next page

Attorneys for Plaintiff, the People of the State of California

APPENDIX

The following additional counsel represent Plaintiff, the People of the State of California, in this 2 action: 3 **ALLISON HALEY** LORI FRUGOLI 4 District Attorney, County of Napa District Attorney, County of Marin 5 Patrick Collins, SBN 253872 Andres Perez, SBN 186219 Deputy District Attorney Deputy District Attorney 6 931 Parkway Mall 3501 Civic Center Drive, Room 130 Napa, CA 94559 San Rafael, CA 94903 7 (707) 253-4211 (415) 473-6450 8 JEANNINE PACIONI TODD SPITZER 9 District Attorney, County of Monterey District Attorney, County of Orange Amy Anderson, SBN 301732 Tracy E. Hughes, SBN 180494 10 Deputy District Attorney Senior Deputy District Attorney 11 1200 Aguajito Road, Room 301 401 Civic Center Drive Monterey, CA 93940 Santa Ana, CA 92701 12 (831) 647-7770 (714) 834-6504 . 13 JILL R. RAVITCH KRISHNA ADAMS 14 District Attorney, County of Sonoma District Attorney, County of Solano Matthew T. Cheever, SBN 191783 Diane M. Newman, SBN 179926 15 Caroline Fowler, SBN 110313 Deputy District Attorney **Deputy District Attorneys** 675 Texas Street, Suite 16 2300 County Center Dr., Ste. B170 Fairfield, CA 94533 17 Santa Rosa, CA 95403 (707) 748-6800 (707) 565-3161 18 19 JEFFREY F. ROSEN JEFFREY ROSELL District Attorney, County of Santa Clara District Attorney, County of Santa Cruz 20 Jennifer Deng, SBN 206285 Douglas Allen, SBN 99239 Deputy District Attorney **Assistant District Attorney** 21 70 W. Hedding St., West Wing 701 Ocean St., Suite 200 22 San Jose, CA 95110 Santa Cruz, CA 95060 (408) 792-2480 (831) 454-2930 23 STEPHANIE BRIDGETT 24 District Attorney, County of Shasta 25 Anand "Lucky" Jesrani, SBN 238252 Senior Deputy District Attorney 26

1355 West Street Redding, CA 96001

(530) 245-6300

27

Exhibit A

RLS 14140481.

FILED ALAMEDA COUNTY

OCT **31** 2016

CLERK OF THE SUPERIOR COURT By Dring Hawas

oputy

NANCY E. O'MALLEY

District Attorney of Alameda County

Matthew L. Beltramo, Deputy District Attorney

(State Bar No. 184796)

7677 Oakport Street, Suite 650

Oakland, CA 94621

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

Telephone: (510) 383-8600 Facsimile: (510) 383-8615

Attorneys for Plaintiff

(For additional Plaintiff's counsel, see Attachment 1 to Stipulation for Entry of Final Judgment)

SUPERIOR COURT OF THE STATE OF CALIFORNIA

IN AND FOR THE COUNTY OF ALAMEDA

PEOPLE OF THE STATE OF CALIFORNIA,

Plaintiff,

VS.

MY PILLOW, INC., a Minnesota Corporation; and MY PILLOW DIRECT, LLC, a Minnesota Limited Liability Company

Defendants.

Case No.: HC16-836619

FINAL JUDGMENT PURSUANT TO STIPULATION

Plaintiff, the People of the State of California, appears through its attorneys: Nancy E. O'Malley, District Attorney of Alameda County, by Matthew L. Beltramo, Deputy District Attorney; Edward S. Berberian, District Attorney of Marin County, by Andres H. Perez, Deputy District Attorney; Dean Flippo, District Attorney of Monterey County, by John Hubanks, Deputy District Attorney; Gary Lieberstein, District Attorney of Napa County, by Patrick Collins, Deputy District Attorney; Tony Rackauckas, District Attorney of Orange County, by Tracy E. Hughes, Deputy District Attorney; Jeffrey F. Rosen, District Attorney of Santa Clara County, by Francisca B. Allen, Deputy District Attorney; Jeffrey Rosell, District Attorney of Santa Cruz County, by Douglas Allen, Assistant District Attorney; Stephen S. Carlton, District Attorney of Shasta County, by Anand "Lucky" Jesrani, Senior Deputy District Attorney; Krishna Abrams,

District Attorney of Solano County, by Diane M. Newman, Deputy District Attorney; and Jill R. Ravitch,

District Attorney of Sonoma County, by Matthew T. Cheever, Deputy District Attorney.

Defendant, My Pillow, Inc., a Minnesota corporation with a registered address of 343 East 82nd Street #102, Chaska, MN 55318, and Defendant My Pillow Direct, LLC, a Minnesota limited liability company with a registered address of 343 East 82nd Street #102, Chaska, MN 55318 (hereinafter, collectively, "Defendants" or "My Pillow"), appear through their attorneys, Beshada and Farnese, LLP, by Peter Farnese, Esquire.

Plaintiff and Defendants (the "Parties") have stipulated that this Final Judgment Pursuant to Stipulation (herein the "Stipulated Final Judgment") may be entered without trial or adjudication of any issue of fact or law. The Parties enter this Final Judgment pursuant to a settlement of certain disputed claims between them as alleged in the Complaint for purposes of avoiding litigation. Nothing in this Final Judgment shall be construed as an admission or denial by Defendants of any fact, issue of law or violations of law alleged generally or specifically in the Complaint.

IT IS HEREBY ORDERED, ADJUDGED, AND DECREED AS FOLLOWS:

- 1. The Stipulated Final Judgment has been reviewed by this Court and is found to have been entered in good faith and to be, in all respects, just, reasonable, equitable and adequate to protect the public from the occurrence in the future of the conduct alleged in the Complaint.
- 2. Unless otherwise stated, all obligations imposed upon Defendants by the terms of this Stipulated Final Judgment are ordered pursuant to sections 17200, et seq., and 17500, et seq., of the California Business and Professions Code, including sections 17203, 17206, and 17535.
 - 3. The Parties waive the right to appeal this Final Judgment both as to form and content.

JURISDICTION

4. This civil enforcement action is brought by Plaintiff in the public interest under the laws of the State of California. As Defendants have offered for sale and/or sold products throughout the State of California, including Alameda County, the Alameda County Superior Court ("Court") has jurisdiction of the subject matter hereof and of the Parties hereto.

APPLICABILITY

5. This Stipulated Final Judgment is applicable to Defendants and to their agents, servants,

employees, representatives, officers, directors, managers, subsidiaries, successors and assigns, and to any and all persons, employees, corporations, and other entities who are acting in concert or participating with Defendants, with actual or constructive notice of this judgment. The Stipulated Final Judgment also applies to Defendants to the extent they are controlling marketing, selling or distributing products through licensees, franchisees or distributors, or in connection with a licensing agreement or product distribution agreement. Whenever the term "Defendants" is used herein, it shall be understood and defined as described above.

6. Nothing in this Stipulated Final Judgment shall excuse the Defendants from meeting any more stringent requirements which may be imposed hereinafter by changes in applicable and legally binding legislation, regulations, ordinances and/or permits.

DEFINITIONS

- 7. The following phrases in this Stipulated Final Judgment have the meaning set forth below:
- A. "ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY" means a clinical study conducted on humans that is randomized, double-blind, placebo-controlled, conducted by persons qualified by training and experience to conduct such study, with statistically significant results as to the claim, advertisement or representation at issue.
- B. "DISEASE" means any damage to an organ, part, structure, or system of the body such that it does not function properly or a state of health leading to such dysfunctioning, including any mental health disease or disorder, and specifically includes the following non-exclusive list of such diseases: allergies, asthma, anxiety, fibromyalgia, insomnia, restless leg syndrome, spine pain (including cervical pain), sleep apnea, snoring, or temporal mandibular joint syndrome (TMJ).
- C. "SUBSTANTIALLY EQUIVALENT DEVICE" shall have the same meaning set forth in section 513(i) of the Food Drug and Cosmetic Act (21 U.S.C. § 360c(i)).

INJUNCTIVE RELIEF

8. Defendants shall be and are hereby permanently enjoined and restrained, pursuant to California Business & Professions Code sections 17203, 17204 and 17535, from doing, directly or indirectly, any of the following within California:



- A. Making or disseminating, or assisting others in making or disseminating, directly or indirectly, expressly or by implication, any claim or advertisement, including any claim or advertisement made through the use of a product name, endorsement, depiction, illustration, labeling or label, consumer testimonial, expert endorsement or other product endorsement, that any pillow product, including but not limited to any pillow marketed or sold under the trade name "MyPillow," can affect the structure or function of the human body or cure, mitigate, treat, or prevent any DISEASE or symptom thereof, unless:
 - the pillow product in question complies with California Health and Safety
 Code section 111550, pertaining to the sale of medical devices; and
 - ii. at the time of making any such claim or representation, it is true, not misleading, and Defendant already has in its possession and relies on at least one ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY conducted on the product or a SUBSTANTIALLY EQUIVALENT DEVICE.

To the extent such claims are made by third-parties and appear on social media accounts affiliated with Defendant (including Facebook), Defendant shall remove such statements as soon as it becomes aware of them.

- B. Violating the provisions of any of the following statutes: California Health and Safety Code section 110400, by delivering in commerce any device that is falsely advertised; California Health and Safety Code section 111440, by manufacturing, selling, delivering, holding, or offering for sale any device that is misbranded; California Health and Safety Code section 111445, by misbranding any device; and/or California Health and Safety Code section 111450, by delivering in commerce any device that is misbranded;
- C. Violating the provisions of California Civil Code section 1770(a)(5), by representing that Defendants' goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities which they do not have or that Defendants have a sponsorship, approval, status, affiliation, or connection which they do not have;

- D. Making and/or disseminating any claim or representation, directly or indirectly, about any user or endorser of any pillow product unless Defendants disclose, clearly and prominently and in visual proximity to any written claim or in temporal proximity to any claim conveyed by voice, any material connection between such user or endorser and any Defendant. For purposes of this Section, a "material connection" shall mean any relationship that materially affects the weight or credibility of the user testimonial or endorsement and that would not reasonably be expected by consumers, including, but not limited to monetary payments from the endorser to the seller, or from the seller to the endorser, or the provision of goods, services, or other benefits to anyone providing a user testimonial or endorsement.
- E. Advertising in any media, including but not limited to television, radio, print,
 Internet or product labels, that any product is an "official" product (or words to that effect) of any
 foundation, non-profit organization or other trade group ostensibly devoted to the study of sleep or
 sleep conditions. In order to give sufficient time for full compliance, Defendants shall have until
 January 31, 2017, to come into compliance with the provisions of Paragraphs 8.D. and 8.E. of this
 Final Judgment.
- 9. Nothing in this Stipulated Final Judgment shall be construed as:
- A. Permitting or allowing Defenadnts to market, advertise, distribute or sell a "medical device" as that term is used in 21 U.S.C. Section 321(h) in violation of the federal statutes, rules or regulations pertaining thereto;
- B. Permitting or allowing Defendants to engage in any violation of law, including any false advertisement, that occurs, takes place or exists as of the time of entry of judgment or at any time thereafter; and
- C. Relieving Defendants of the obligation to follow any applicable law or statute not referenced herein.
- 10. Any amended statute or regulation, successor statute or regulation or renumbered statute or regulation will have the same force and effect as the statutes and regulations cited in this Final Judgment.

MONETARY RELIEF

- 11. Pursuant to Business and Professions Code sections 17203, 17206, 17535 and 17536, Defendants shall make monetary payments in this matter is as set forth below:
 - A. Restitution: As Defendant My Pillow, Inc., has previously agreed to pay restitution to California consumers in connection with an independent and uncoordinated class action lawsuit styled Amiri v. My Pillow, Inc. (San Bernardino Superior Court Docket #CIVDS 1606479, filed Apr. 26, 2016), the Court therefore orders that additional restitution in this matter shall take the form of cy pres in the amount of one hundred thousand dollars (\$100,000.00). Said restitution shall be paid to non-profit organizations that provide or support overnight sleeping accommodations to those in need of assistance, including the homeless and those who are victims of domestic violence, as set forth in Schedule A, attached hereto. Defendants shall issue separate cashier checks payable to each recipient organization in the respective amounts set forth therein. The checks shall be delivered via overnight mail or hand delivery to Deputy District Attorney Matthew Beltramo no later than five (5) business days after the date of entry of this Final Judgment.
 - B. <u>Civil Penalties</u>: Defendants are hereby jointly and severally ordered pursuant to Business & Professions Code sections 17206 and 17536, to pay civil penalties in the total amount of nine hundred ninety-five thousand dollars (\$995,000.00). Civil penalties shall paid in the form of cashier's check, money order or trust fund check and shall made payable to the "Marin County District Attorney's Office," which office shall distribute the payment in equal amounts between the District Attorney offices representing the People in this action, in accordance with Business and Professions Code section 17206 and Government Code Section 26506. The cashier's check or money order shall be delivered via hand delivery or overnight mail to Deputy District Attorney Matthew Beltramo no later than there (3) business days after the date this judgment is entered.

COMPLIANCE

12. For the purpose of securing compliance with the terms of this Stipulated Final Judgment,

Defendants are hereby ordered and mandated to do all of the following:

- A. Defendants shall create, maintain and make available to any representative of the People for inspection and copying, within fifteen (15) days of any written request to do so, the following:
 - i. all written documents from or correspondence with the Food and Drug

 Administration regarding any approval for use or exemption described in paragraph 8(A)(i),

 above;
 - ii. all ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDIES for the types of claims described above. Each such ADEQUATE AND WELL-CONTROLLED HUMAN CLINICAL STUDY shall contain the date of its inclusion in this file, and shall be maintained for at least five (5) years from the date of its inclusion in this file; and
 - iii. A file that contains all tests, reports, studies, surveys, demonstrations, information or other evidence in Defendants' possession or control, if any, that contradict, qualify or call into question any claim or representation made and/or disseminated for any of Defendants' products, or that contradict, qualify or call into question the basis upon which Defendants relied on such claim or representation, including but not limited to complaints from consumers and complaints or inquiries from governmental organizations. For each such item, the date of its inclusion in the file shall be noted, and such item shall be maintained for at least five (5) years from the date of its inclusion in this file.
- B. Within thirty (30) days of the date of the entry of this Stipulated Final Judgment,
 Defendants shall provide a copy of this Final Judgment to each of their current principals, officers,
 directors and managers, affiliates, subsidiaries and to all personnel, agents and representatives
 having primary authority over sales, advertising or policy responsibility with respect to the subject
 matter of this Final Judgment and shall obtain from each such person a legible signed written
 acknowledgment indicating that he or she has received a copy of this Final Judgment, read it,
 understood its terms, and agreed to fully abide by all of its terms. Defendants shall provide written

verification of such acknowledgments to the People within fifteen (15) days of any written request to do so;

C. For a period of five (5) years after entry of this Stipulated Final Judgment,
Defendants shall provide a copy of this Final Judgment to each of their future principals, officers,
directors and managers, future affiliates, future subsidiaries, and to all future personnel, agents and
representatives having primary authority over sales, advertising or policy responsibility with
respect to the subject matter of this judgment within ten (10) days after the person commences his
or her responsibilities. Defendants shall obtain from each such person a legible signed written
acknowledgment indicating that he or she received a copy of this Stipulated Final Judgment, read it,
understood its terms, and agreed to fully abide by all of its terms. Defendants shall maintain and
upon request make available, within fifteen (15) days of receipt of a written request, to
representatives of the People for inspection and copying, all such legible signed written
acknowledgments.

JURISDICTION RETAINED

Jurisdiction is retained for the purposes of enabling any party to this Stipulated Final Judgment to apply to the Court at any time for such order or directions as may be necessary or appropriate for the construction of or carrying out of this Stipulated Final Judgment, for the modification or termination of any of the injunctive provisions thereof, for the enforcement of compliance therewith, or for the punishment of violations thereunder.

EFFECT AND ENTRY

		_ :					
14.	This Cine	Indome	ahall talca	affaat imamaa	diatalreman	entry hereof.	
14.	I IIIS FIIIZI	Juagment	snan take	CHECK MIMILE	TIMICIA MODII	CHILLA TICLEOT	٠
						/ - \	

DATED:	10	/31	16	
				_

By:

Judge of the Superior Court

MORRIS LACOBSON

SCHEDULE A: NON-PROFIT SHELTERS

Name of Shelter (Payee)	Address	EIN	Amount
Homeward Bound of Marin	1385 N. Hamilton Parkway Novato, CA 94949	68-0011405	\$10,000
Safe Alternatives to Violent Environments Inc.	1900 Mowry Ave, Suite 201 Fremont, CA 94538	94-2520559	\$10,000
Shasta Women's Refuge (d/b/a One Safe Place)	2280 Benton Drive, Suite A Redding, CA 96003	94-2663045	\$10,000
Napa Emergency Women's Services	1141 Pear Tree Lane, Suite 220 Napa, CA 94558	94-2745889	\$10,000
Safequest Solano	1049 Union Ave, Suites B & C Fairfield, CA 94533	94-2853669	\$10,000
Asian Americans for Community Involvement of Santa Clara County (d/b/a Asian Women's Home)	2400 Moorpark Ave San Jose, CA 95128	94-2292491	\$2,000
Maitri	PO Box 697 Santa Clara, CA 95052	94-3132087	\$2,000
Young Women's Christian Association of Silicon Valley	375 South Third Street San Jose CA 95112	94-1186196	\$2,000
Community Solutions for Children Families and Individuals	16264 Church Street, Suite 103, Morgan Hill, CA 95037	23-7351215	\$2,000
Next Door Solutions to Domestic Violence	234 E Gish Rd #200 San Jose, CA 95112	94-2420708	\$2,000
Community Action Partnership of Sonoma County	141 Stony Circle, Suite # 210 Santa Rosa, CA 95401	94-1648949	\$10,000
Mercy House Living Centers (d/b/a Mercy House)	P.O. Box 1905 Santa Ana, CA 92702	33-0315864	\$10,000
Pass The Word Ministry (d/b/a We Help Homeless Women)	P.O. Box 2674 Monterey, CA 93942	45-2534088	\$10,000
Walnut Avenue Family and Women's Center	303 Walnut Ave Santa Cruz, CA 95060	94-1186.197	\$5,000
Monarch Services Inc.	1509 Seabright Ave. C-1, Santa Cruz, CA 95062	94-2462783	\$5,000
		Total:	\$100,000